1. P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN. (23rd June 2022) Authors: Rodriguez, C.; Kaufman, J. L.; Laubach, J.; Sborov, D. W.; Reeves, B.; Chari, A.; Silbermann, R.; Costa, L. J.; Anderson, L. D.; Nathwani, N.; Shah, N.; Bumma, N.; Jakubowiak, A.; Orlowski, R. Z.; Pei, H.; Cortoos, A.; Patel, S.; Lin, T. S.; Richardson, P. G.; Voorhees, P. M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 824 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PB2012: A PHASE 2 MULTIARM STUDY OF MAGROLIMAB COMBINATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Paul, B.; Liedtke, M.; Siegel, D. S.; Khouri, J.; Hillenglass, J.; Rifkin, R.; Gandhi, M. D.; Kin, A.; Levy, M. Y.; Mohrbacher, A.; Schmidt, W.; Silbermann, R.; Cottini, F.; Sborov, D. W.; Walker, R.; Murphy, M.; Gu, L.; Chen, A.; Rajakumaraswamy, N.; Usmani, S. Z. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1883 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗